FDA Brief

Warning letters Food

FDA warning letter to

DRF LLC

High riskIssued Apr 21, 2021Posted Jun 22, 2021Office of Human and Animal Foods Operations- West Division

FDA warned DRF LLC that Boston C, Mega-Dose Vitamin C, and Pixie Dust Magnesium were unapproved drugs promoted for treating cancer.

What happened

FDA reviewed the websites doctorfarrah.com and drfarrah.online in February and March 2021, plus an Instagram page that directed consumers to the website to buy the products. The websites claimed the products could treat, cure, or prevent diseases including cancer, infections, diabetes, depression, and other serious conditions. FDA determined the products were unapproved new drugs and misbranded because they lacked adequate directions for these disease uses.

What FDA found

  1. Website claims said Boston C, Mega-Dose Vitamin C, and Pixie Dust Magnesium are intended to cure, mitigate, treat, or prevent diseases, making them drugs.

    section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. The products are not generally recognized as safe and effective for those disease uses, so they are unapproved new drugs.

    section 201(p) of the Act [21 U.S.C. 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]
  3. The products lack adequate directions for use for diseases that a layperson cannot safely self-diagnose or treat without a licensed practitioner.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. Selling these misbranded drugs across state lines violates the Act.

    section 301(a) of the Act [21 U.S.C. 331(a)]

What FDA wants

Within 15 working days of receipt, notify FDA in writing of the specific steps taken to correct the violations and prevent recurrence, with supporting documentation, or explain why more time is needed and when correction will be complete. If DRF LLC believes the products are not in violation, it must include its reasoning and supporting information.

Who should pay attention

  • dietary supplement brands making disease-treatment claims
  • online sellers of health products
  • companies using social media influencers to promote products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk